Purpose of Review <p>Until recently, the management of anaphylaxis has been dependent on the avoidance of known triggers combined with the emergent treatment of immediate and, possibly, fatal hypersensitivity reactions. The approval of omalizumab for the prevention of food-induced anaphylaxis heralds a new era for the use of biologics to curtail anaphylactic reactions in susceptible individuals.</p> Recent Findings <p>As more knowledge is gleaned about the immunologic mechanisms of anaphylaxis, the application of biologics for prophylaxis of anaphylaxis has accelerated.</p> Summary <p>While omalizumab is currently the only approved biologic for averting anaphylaxis, data is accumulating for the use of other biologics as well. These include monoclonal antibodies that target IgE, mast cell receptors, cytokines, and alarmins.</p>